Stem definition | Drug id | CAS RN |
---|---|---|
beta-adrenoreceptor antagonists | 356 | 63659-18-7 |
Dose | Unit | Route |
---|---|---|
20 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.45 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 15 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 2.17 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 85 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 4.80 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 3.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.40 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 17 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 30, 1985 | FDA | ALCON |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Limb injury | 57.13 | 25.42 | 25 | 2411 | 21385 | 53325245 |
Stevens-Johnson syndrome | 53.82 | 25.42 | 25 | 2411 | 24557 | 53322073 |
Hyperaesthesia | 51.13 | 25.42 | 18 | 2418 | 8671 | 53337959 |
Fall | 47.22 | 25.42 | 69 | 2367 | 358371 | 52988259 |
Transient ischaemic attack | 44.98 | 25.42 | 25 | 2411 | 35700 | 53310930 |
Angioplasty | 40.87 | 25.42 | 10 | 2426 | 1354 | 53345276 |
Haemorrhage | 38.47 | 25.42 | 27 | 2409 | 57960 | 53288670 |
Peripheral vascular disorder | 37.26 | 25.42 | 13 | 2423 | 6095 | 53340535 |
Glaucoma | 36.30 | 25.42 | 17 | 2419 | 16986 | 53329644 |
Crepitations | 35.88 | 25.42 | 13 | 2423 | 6796 | 53339834 |
Choking | 35.44 | 25.42 | 14 | 2422 | 9262 | 53337368 |
Acquired haemophilia | 33.61 | 25.42 | 8 | 2428 | 964 | 53345666 |
Bradycardia | 33.57 | 25.42 | 27 | 2409 | 71029 | 53275601 |
Fungal infection | 31.13 | 25.42 | 19 | 2417 | 32227 | 53314403 |
Status epilepticus | 28.80 | 25.42 | 14 | 2422 | 15170 | 53331460 |
Urinary retention | 28.06 | 25.42 | 17 | 2419 | 28449 | 53318181 |
Sputum discoloured | 26.54 | 25.42 | 13 | 2423 | 14326 | 53332304 |
Low density lipoprotein increased | 26.00 | 25.42 | 10 | 2426 | 6156 | 53340474 |
Wound | 25.80 | 25.42 | 26 | 2410 | 91531 | 53255099 |
Cardiac failure congestive | 25.51 | 25.42 | 26 | 2410 | 92731 | 53253899 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Wrong drug | 41.38 | 26.97 | 6 | 832 | 81 | 32512607 |
Splenic rupture | 34.12 | 26.97 | 8 | 830 | 1613 | 32511075 |
Source | Code | Description |
---|---|---|
ATC | C07AB05 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Beta blocking agents, selective |
ATC | S01ED02 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Beta blocking agents |
ATC | S01ED52 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Beta blocking agents |
FDA MoA | N0000000161 | Adrenergic beta-Antagonists |
FDA EPC | N0000175556 | beta-Adrenergic Blocker |
CHEBI has role | CHEBI:35530 | beta-adrenoceptor antagonists |
CHEBI has role | CHEBI:35674 | antihypertensive |
CHEBI has role | CHEBI:66991 | sympatholytics |
MeSH PA | D018663 | Adrenergic Agents |
MeSH PA | D018674 | Adrenergic Antagonists |
MeSH PA | D058671 | Adrenergic beta-1 Receptor Antagonists |
MeSH PA | D000319 | Adrenergic beta-Antagonists |
MeSH PA | D000959 | Antihypertensive Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D013565 | Sympatholytics |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Ocular hypertension | indication | 4210003 | DOID:9282 |
Hypertensive disorder | indication | 38341003 | DOID:10763 |
Open-angle glaucoma | indication | 84494001 | DOID:1067 |
Malignant glaucoma | off-label use | 10100008 | |
Aphakic glaucoma | off-label use | 15374009 | |
Secondary glaucoma | off-label use | 95717004 | |
Bronchospasm | contraindication | 4386001 | |
Psoriasis | contraindication | 9014002 | DOID:8893 |
Complete atrioventricular block | contraindication | 27885002 | |
Acute cerebrovascular insufficiency | contraindication | 29322000 | |
Depressive disorder | contraindication | 35489007 | |
Anaphylaxis | contraindication | 39579001 | |
Chronic heart failure | contraindication | 48447003 | |
Sinus bradycardia | contraindication | 49710005 | |
Acute nephropathy | contraindication | 58574008 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Pulmonary emphysema | contraindication | 87433001 | |
Cardiogenic shock | contraindication | 89138009 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Second degree atrioventricular block | contraindication | 195042002 | |
Decompensated cardiac failure | contraindication | 195111005 | |
Asthma | contraindication | 195967001 | DOID:2841 |
Heart block | contraindication | 233916004 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Hypoglycemic disorder | contraindication | 237630007 | |
Raynaud's phenomenon | contraindication | 266261006 | |
Pregnancy, function | contraindication | 289908002 | |
Pheochromocytoma | contraindication | 302835009 | |
Acute exacerbation of asthma | contraindication | 708038006 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.19 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-1 adrenergic receptor | GPCR | ANTAGONIST | Kd | 8.80 | WOMBAT-PK | CHEMBL | |||
Beta-2 adrenergic receptor | GPCR | Kd | 7.20 | WOMBAT-PK | |||||
Beta-2 adrenergic receptor | GPCR | Kd | 6.98 | CHEMBL | |||||
Beta-2 adrenergic receptor | GPCR | IC50 | 6.18 | CHEMBL | |||||
Beta-1 adrenergic receptor | GPCR | Kd | 8.53 | CHEMBL | |||||
Beta-1 adrenergic receptor | GPCR | Kd | 8.76 | CHEMBL |
ID | Source |
---|---|
4019633 | VUID |
N0000147726 | NUI |
D00598 | KEGG_DRUG |
63659-19-8 | SECONDARY_CAS_RN |
142144 | RXNORM |
C0005320 | UMLSCUI |
CHEBI:3082 | CHEBI |
CHEMBL423 | ChEMBL_ID |
CHEMBL1691 | ChEMBL_ID |
DB00195 | DRUGBANK_ID |
D015784 | MESH_DESCRIPTOR_UI |
2369 | PUBCHEM_CID |
549 | IUPHAR_LIGAND_ID |
4530 | INN_ID |
O0ZR1R6RZ2 | UNII |
31545 | MMSL |
4280 | MMSL |
d00176 | MMSL |
001859 | NDDF |
004743 | NDDF |
349900007 | SNOMEDCT_US |
387195001 | SNOMEDCT_US |
409276006 | SNOMEDCT_US |
4018588 | VANDF |
4019633 | VANDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Betoptic S | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0065-0246 | SUSPENSION/ DROPS | 2.80 mg | OPHTHALMIC | NDA | 25 sections |
Betaxolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-623 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 19 sections |
Betaxolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-624 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 19 sections |
BETAXOLOL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-013 | TABLET, COATED | 10 mg | ORAL | ANDA | 12 sections |
BETAXOLOL HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-014 | TABLET, COATED | 20 mg | ORAL | ANDA | 12 sections |
Betaxolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-705 | SOLUTION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 19 sections |
Betaxolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24658-700 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 17 sections |
Betaxolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24658-701 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 17 sections |
Betaxolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42806-038 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 17 sections |
Betaxolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42806-039 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 17 sections |
Betaxolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4932 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 17 sections |
Betaxolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60429-753 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 12 sections |
Betaxolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60429-754 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 12 sections |
Betaxolol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61314-245 | SOLUTION/ DROPS | 5.60 mg | OPHTHALMIC | NDA authorized generic | 19 sections |